 Outlook Therapeutics intends to use the net proceeds from the offering for working capital and general corporate purposes, including in support of its ONS-5010 development program. The shares of common stock offered in the offering were offered and sold by Outlook Therapeutics pursuant to a shelf registration statement on Form S-3 Registration No. 333-231922, including a base prospectus, previously filed with and declared effective by the Securities and Exchange Commission SEC on June 26, 2019. 